SFM
CMMB

Sphera Funds Management’s Chemomab Therapeutics CMMB Stock Holding History

Sphera Funds Management’s Portfolio CMMB Stock Details CMMB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-179,425
Closed -$472K – 108
2025
Q3 		$472K Sell
179,425
-5,087
-3% -$18.8K 0.1% 106
2025
Q2 		$856K Sell
184,512
-40,595
-18% -$201K 0.2% 92
2025
Q1 		$981K Sell
225,107
-78,537
-26% -$551K 0.23% 91
2024
Q4 		$2.2M Hold
303,644
– – 0.4% 80
2024
Q3 		$1.91M Buy
+303,644
New +$1.7M 0.3% 87

Other funds holding CMMB

Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return
KPWS
Kestra Private Wealth Services Austin, Texas $9.1B AUM 32.09% 1-Year Est. Return
XT
XTX Topco George Town, Cayman Islands $7.72B AUM 32.88% 1-Year Est. Return
RhumbLine Advisers
RhumbLine Advisers Boston, Massachusetts $133B AUM 43.5% 1-Year Est. Return
Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return
VF
Virtu Financial New York $3.18B AUM 65.92% 1-Year Est. Return
BNP Paribas Financial Markets
BNP Paribas Financial Markets Paris, France $289B AUM 60.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Sphera Funds Management's CMMB Position: Q4 2025 in Review

Sphera Funds Management sold out of Chemomab Therapeutics (CMMB) in Q4 2025, closing a stake of 179,425 shares — an estimated $472K sold.

Sphera Funds Management first reported a position in CMMB in Q3 2024 and held it in 5 quarters. The position peaked at $2.2M in Q4 2024. 14 funds tracked by Wall St. Rank hold CMMB as of Q4 2025.

  • Sphera Funds Management reported no remaining Chemomab Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Sphera Funds Management sold 179,425 Chemomab Therapeutics shares in Q4 2025, an estimated $472K.
  • Sphera Funds Management first reported a position in Chemomab Therapeutics in Q3 2024 and held it in 5 quarters.
  • Sphera Funds Management's Chemomab Therapeutics position peaked at $2.2M in Q4 2024.
  • 14 funds tracked by Wall St. Rank held Chemomab Therapeutics as of Q4 2025.

Based on Sphera Funds Management's 13F filing for Q4 2025, filed 17 Feb 2026.